STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaksSTAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more. Can a GLP-1 drug slow Alzheimer’s Read More
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progressionSTAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as Read More
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event riskDulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with type 2 diabetes (T2DM). 2. All three agents were associated with an increased risk of gastrointestinal AEs, particularly motility-related events, compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2is). Evidence Rating Level: 2 (Good) Study Rundown: GLP-1 receptor Read More
Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial findsDaily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds
A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher. A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose Read More
Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s whyMaking GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars. The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement Read More
New evidence shows tirzepatide and semaglutide strongly protect the heartNew evidence shows tirzepatide and semaglutide strongly protect the heart
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs. A massive real-world study comparing tirzepatide and Read More
Why some people are microdosing GLP-1Why some people are microdosing GLP-1
NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications. NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications.
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in ValueEli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone. The 150-year-old drugmaker is the first company in health care to hit the milestone.
Opinion: Trump’s regressive deal on GLP-1s misses the mark for patients like meOpinion: Trump’s regressive deal on GLP-1s misses the mark for patients like me
The U.S. government is finally flexing its negotiating muscle to reduce GLP-1 prices and expand access to these medicines — for weight loss — in federal health programs. President Trump’s much-anticipated “deal” with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the Read More
Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapyQ&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy
People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in their health, such as improved blood sugar, lower blood pressure and weight loss. People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in Read More